Business Case for a Clinical Pharmacy Specialist

Australian family medicine practices carry a familiar burden: many patients take several medicines, attend more than one service and struggle to navigate changes made during a hospital admission. A business case for adding a clinical pharmacy specialist should show how a medicines expert releases clinician time, improves continuity and reduces avoidable medication harm. The role is most persuasive when presented as part of the care team rather than as another activity shifted onto an already busy pharmacist.

The strongest case combines operational evidence with patient and staff experience. It should identify a defined problem, calculate the full cost of the role, test whether benefits are credible, and set out how the service will be governed. It also needs a realistic funding pathway because most clinical pharmacist work in Australian general practice is not funded through a standard general-practice Medicare item. Practices should therefore treat the proposal as an investment in quality and capacity while remaining explicit about who will pay.

Define the role before counting the cost

A clinical pharmacy specialist working inside the practice is different from a community pharmacist who mainly dispenses and advises at the counter. The embedded professional can undertake comprehensive medication reviews, reconcile lists after transitions of care, assess adherence and interactions, support deprescribing, and prepare precise recommendations for the general practitioner. In mental health and addiction services, the same role can review psychotropic medicines, withdrawal risks and safety plans while working alongside the treating team.

Begin with a baseline audit rather than a general claim about medication safety. Practices can extract de-identified information on medicine counts, high-risk combinations, allergy documentation, discharge summaries, referral patterns and time spent resolving prescription queries. A 12-month period is more useful than a single week because seasonal prescribing, PBS safety-net changes and local hospital discharge patterns can distort the picture. Include clinician time, patient feedback and examples of near misses so that the proposed role addresses observed work rather than an assumed problem.

Define a written scope before recruitment. State which patients receive the service, what a review involves, how urgent findings are escalated, who follows recommendations and how the pharmacist collaborates with the patient’s usual community pharmacy. Unless a lawful state arrangement applies, the clinical pharmacist should not act as an independent prescriber. A clear role also protects continuity: the general practitioner retains diagnostic responsibility and prescribing authority, while the specialist contributes concentrated medicines expertise.

Anchor the proposal in Australian primary care

Australian primary care has a mixed funding model. Medicare and the Pharmaceutical Benefit Scheme support much of the treatment pathway, but a general practice is usually a private business that bills MBS items rather than receiving an automatic salary for every team member. Practices in Melbourne, Brisbane and regional centres often operate with slim margins, so a proposal that assumes significant new income will attract scrutiny. Plausible funding could include practice revenue, a Primary Health Network, a state workforce program, a grant, or a shared arrangement with a local health service.

Geography changes both need and delivery. A pharmacist embedded in a large metropolitan practice can support telehealth and scheduled clinics, while services in rural Queensland, northern Western Australia or the Northern Territory may need travel, outreach and stronger links with hospitals, aged care and Aboriginal community-controlled health organisations. Around Alice Springs, for example, cultural safety, trusted local relationships and Aboriginal workforce participation are central to any medication service. Pharmacist expertise can support those relationships, but it should not replace community leadership or the practice’s existing cultural governance.

Everyday language also shapes uptake. Patients may call prescriptions “scripts”, ask for a “repeat”, or refer to a “chemist” when they mean a community pharmacy. Using familiar terms while explaining the clinical purpose of a review can improve engagement, especially for people with limited English or low health literacy. State rules on pharmacist prescribing, vaccine administration and medicine supply vary, so local legal pathways must be checked. These differences can affect costs, but the central proposal should remain consistent: coordinated medicines advice close to the patient’s general practitioner.

Quantify value and cost with evidence

A credible financial model separates cash benefits from value that is harder to attribute. Direct savings might include avoided duplication, reduced follow-up calls, fewer medication-related hospital presentations and more efficient use of appointment slots. Capacity benefits include pharmacist-led reviews that return time to GPs and nurses, or additional appointments enabled when treatment is stabilised. Quality benefits may be substantial but should not be converted into speculative dollar claims without evidence. A simple calculation—annual benefits minus annual operating costs—gives decision-makers a transparent starting point.

Use conservative assumptions and show the calculation. Attribute only benefits that the service can reasonably influence, apply a probability to uncertain events and flag where the practice lacks data. Reports from the local health service, de-identified practice data, the PBS and Primary Health Network information can provide context. Where emergency department attendance rises, do not claim that every additional attendance was caused by medicines. The aim is a defensible range, such as a cautious case, expected case and upside case, rather than a single overly precise forecast.

Include every cost: salary and employer on-costs, superannuation, workers compensation, professional indemnity, continuing education, supervision, software, equipment, space, training and administration. Add backfill for leave and any time required of the general practitioner to discuss recommendations. An embedded worker also carries opportunity costs because rooms and systems used for pharmacy consultations cannot serve other activities. Part-time delivery may lower the initial commitment, but it can also fragment care unless patients, staff and community pharmacy colleagues know when the pharmacist is available.

Complex medicines show why integration matters. A practical example is community pharmacy ADHD guidance, which illustrates how dispensing settings can support safer stimulant prescribing, follow-up and consumer education. The embedded clinical pharmacist can connect that work with medical record review, mental health assessment and agreed escalation pathways. No single clinical outcome should be promised from the link alone; its value is as one example of shared protocols across the patient journey.

Design the service around safe clinical work

Start with a limited pilot built around a defined cohort, such as older people taking five or more medicines, people discharged from hospital, or patients with diabetes, anticoagulants or complex mental health treatment. A warm referral from the general practitioner works better than a stand-alone referral form because the purpose and expected workload are clear. The pharmacist should review the record, invite the patient to a dedicated appointment, document findings and send concise recommendations with a response deadline.

Integrate the role into the practice rather than bolting it onto the day. Use the shared medical record, a standardised medicines reconciliation process and a clear route for urgent concerns about allergies, interactions, adherence, opioid medicines or other controlled substances. A supervising pharmacist and clinical governance group should review cases, measure safety and support continuing professional development. Privacy remains important: information shared with community pharmacies or external clinicians should follow consent and secure electronic transmission requirements.

Design access for the whole community. Offer telehealth, phone appointments, interpreter support and outreach where local services allow, while checking whether private fees, transport or digital exclusion create barriers. In places such as Darwin, Katherine or outer-regional Queensland, flexibility may be as important as the number of consultations. Patients should know what the service costs, whether Medicare covers it and how a review differs from a routine dispensing interaction. A co-contribution may be viable for some services but should be tested before excluding lower-income patients.

Track a balanced set of measures from the beginning: time to first review, recommendations accepted, medicines changed, adherence and understanding, patient-reported experience, staff workload, falls, hypoglycaemia, medication-related admissions and any adverse events. Review trends at three, six and twelve months, then compare them with the baseline. Document the denominator, data source and attribution method so improvements are not confused with seasonal variation. Patient stories and staff feedback can explain numerical results and reveal barriers that a dashboard alone will miss.

Compare options and secure approval

Compare delivery models against the problem rather than an assumed staffing number. The options differ in capacity, continuity, cost and governance. A smaller model may suit a stable, low-complexity practice; a practice with rapid growth, hospital transitions or a large high-risk population may justify more substantial capacity.

Model Best fit Main strengths Main limitation Funding approach
Full-time embedded specialist Complex, high-volume or rapidly growing practice Strong continuity, direct record access and rapid escalation Highest fixed cost and commitment Practice funds, with PHN or state support where available
Part-time or hybrid specialist Lower-volume practice or geographically dispersed team Flexible coverage and manageable start-up cost Less predictable availability and slower relationship building Blended practice, grant or regional funding
Contracted clinical pharmacist Practices wanting targeted project support Fast to arrange and useful for a defined pilot Fragmented workflow and variable continuity Time-limited agreement or project funding
Community pharmacy referral pathway Medication access and brief counselling needs Convenient, familiar setting and broad reach Limited record access and scope for complex review Routine dispensing revenue or funded service agreement

Turn the preferred model into a short decision pack: the clinical problem and baseline, proposed scope, staffing level, annual budget, conservative benefit scenarios, workflow, governance, risks and a funding decision. Give the practice owner, clinical lead, practice manager and finance owner named responsibilities. Set gates at pilot approval, three months and twelve months, with thresholds for continuing, expanding or revising the service. Do not rely on hypothetical Medicare rebates unless a current, eligible pathway has been confirmed.

Secure approval by connecting the investment to outcomes leadership already values: safer prescribing, continuity for older and medically complex patients, fewer avoidable transitions, stronger preventive care and a more resilient clinical team. Present the proposal at the next practice meeting with the baseline audit, option analysis and one-year budget. Then appoint an executive sponsor, confirm the funding source, recruit or contract the pharmacist and schedule the first governance review. That sequence turns a valuable clinical idea into a tested service with accountable ownership.